Delray Beach, Florida, United States Auven Therapeutics is the famous VC, which was founded in 2007. The main department of described VC is located in the Delray Beach. The company was established in North America in United States.
The increased amount of exits for fund were in 2016. Deals in the range of 50 - 100 millions dollars are the general things for fund. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Auven Therapeutics performs on 4 percentage points less the average number of lead investments. The top activity for fund was in 2009. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 investment rounds annually.
The fund was created by Peter Corr. The overall number of key employees were 2.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Auven Therapeutics, startups are often financed by AstraZeneca, Tichenor Ventures, Purdue Pharma. The meaningful sponsors for the fund in investment in the same round are AstraZeneca, Tichenor Ventures, Redmile Group. In the next rounds fund is usually obtained by AstraZeneca, HBM Healthcare Investments AG, Tichenor Ventures.
Among the most popular fund investment industries, there are Health Care, Medical. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Spirogen, Kolltan Pharmaceuticals.
Related Funds
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ADC Therapeutics | $80M | 02 Sep 2015 | Lausanne, Vaud, Switzerland | ||
ADC Therapeutics | $40M | 16 Oct 2013 | Lausanne, Vaud, Switzerland | ||
ADC Therapeutics | $50M | 26 Mar 2012 | Lausanne, Vaud, Switzerland | ||
Kolltan Pharmaceuticals | $10M | 20 Jan 2010 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $5M | 12 Oct 2009 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $40M | 31 Jul 2008 | New Haven, Connecticut, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ADC Therapeutics | $80M | 02 Sep 2015 | Lausanne, Vaud, Switzerland | ||
ADC Therapeutics | $40M | 16 Oct 2013 | Lausanne, Vaud, Switzerland | ||
ADC Therapeutics | $50M | 26 Mar 2012 | Lausanne, Vaud, Switzerland | ||
Kolltan Pharmaceuticals | $10M | 20 Jan 2010 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $5M | 12 Oct 2009 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $40M | 31 Jul 2008 | New Haven, Connecticut, United States |
